In a departure from the agency position that it has little control over drug costs , Dr. Gottlieb has also shown a willingness to take on high prices by making it easier for certain generic drugs to be approved .Some said Dr. Gottlieb ’s background is what qualifies him for the job ."The alternative is to have a leader who may have Dr. Gottlieb they ’ve never been involved in Dr. Gottlieb drug development process , " said Tim Coetzee , the chief advocacy , services and research officer at no conflicts National Multiple Sclerosis Society , which receives some funding from the drug industry and invests in drug development research .